Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03030300|
Recruitment Status : Completed
First Posted : January 25, 2017
Last Update Posted : January 25, 2017
|Condition or disease||Intervention/treatment||Phase|
|Type2 Diabetes||Drug: Novolin 30R;Pioglitazone;Metformin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||170 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||February 2015|
|Actual Study Completion Date :||February 2015|
Experimental: Novolin 30R;Pioglitazone;Metformin
Drugs: Insulin (Novolin 30R) monotherapy or combined with one or two oral drugs (metformin 0.5 mg tid and pioglitazone hydrochloride 15 mg qd).
Drug: Novolin 30R;Pioglitazone;Metformin
- prolonged-remission rate [ Time Frame: 5 years ]hyperglycemia below diagnostic thresholds for diabetes without active pharmacologic therapy or ongoing procedures of 5 years' duration.
- partial-remission rate [ Time Frame: 5 years ]hyperglycemia below diagnostic thresholds for diabetes without active pharmacologic therapy or ongoing procedures of more than 3 months' duration, and less than 5 years.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03030300
|Shandong Provincial Hospital|
|Jinan, Shandong, China, 250001|
|Jinan, Shandong, China, 250012|
|Jinan, Shandong, China, 250014|
|Study Chair:||Lin Liao, MD||Qianfoshan Hospital|